{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T09:07:19Z","timestamp":1774343239530,"version":"3.50.1"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.jneuroim.2017.05.006","type":"journal-article","created":{"date-parts":[[2017,5,12]],"date-time":"2017-05-12T05:27:29Z","timestamp":1494566849000},"page":"47-50","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["CD4\/CD8 ratio during natalizumab treatment in multiple sclerosis patients"],"prefix":"10.1016","volume":"309","author":[{"given":"Antonio","family":"Carotenuto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Scalia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Ausiello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcello","family":"Moccia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cinzia Valeria","family":"Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Sacc\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"De Rosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Criscuolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Del Vecchio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Brescia Morra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Lanzillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2017.05.006_bb0005","first-page":"259","article-title":"Co-infection with two JC virus genotypes in brain, cerebrospinal fluid or urinary tract detected by direct cycle sequencing of PCR products","volume":"2","author":"Agostini","year":"1996","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.jneuroim.2017.05.006_bb0010","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2017.05.006_bb0015","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1136\/jnnp-2013-306936","article-title":"Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results","volume":"85","author":"Butzkueven","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jneuroim.2017.05.006_bb0020","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/infdis\/147.4.676","article-title":"Persistence of DNA sequences of BK virus and JC virus in normal human tissues and in diseased tissues","volume":"147","author":"Chesters","year":"1983","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jneuroim.2017.05.006_bb0025","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000109933","article-title":"Natalizumab: targeting alpha4-integrins in multiple sclerosis","volume":"5","author":"Engelhardt","year":"2008","journal-title":"Neurodegener. Dis."},{"key":"10.1016\/j.jneuroim.2017.05.006_bb0030","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ana.22128","article-title":"Anti-JC virus antibodies: implications for PML risk stratification","volume":"68","author":"Gorelik","year":"2010","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2017.05.006_bb0035","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/jmv.1890080208","article-title":"The persistence of papovavirus BK DNA sequences in normal human renal tissue","volume":"8","author":"Heritage","year":"1981","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.jneuroim.2017.05.006_bb0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0160277","article-title":"Natalizumab affects T-cell phenotype in multiple sclerosis: implications for JCV reactivation","volume":"11","author":"Iannetta","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jneuroim.2017.05.006_bb0045","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/cei.12261","article-title":"Long-term follow-up of peripheral lymphocyte subsets in a cohort of multiple sclerosis patients treated with natalizumab","volume":"176","author":"Koudriavtseva","year":"2014","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.jneuroim.2017.05.006_bb0050","first-page":"807","article-title":"JC virus antibody index in natalizumab-treated patients: correlations with John Cunningham virus DNA and C-reactive protein level","volume":"10","author":"Lanzillo","year":"2014","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.jneuroim.2017.05.006_bb0055","first-page":"10","article-title":"Sensitivity of the epidemic and pandemic influenza virus strains to zanamivir (Relenze) in in vitro experiments","volume":"55","author":"L'vov","year":"2010","journal-title":"Vopr. Virusol."},{"key":"10.1016\/j.jneuroim.2017.05.006_bb0060","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1146\/annurev.med.080708.082655","article-title":"Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies","volume":"61","author":"Major","year":"2010","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.jneuroim.2017.05.006_bb0065","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1086\/504811","article-title":"Infectious complications associated with alemtuzumab use for lymphoproliferative disorders","volume":"43","author":"Martin","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jneuroim.2017.05.006_bb0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0081685","article-title":"Increased B cell and cytotoxic NK cell proportions and increased T cell responsiveness in blood of natalizumab-treated multiple sclerosis patients","volume":"8","author":"Mellergard","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jneuroim.2017.05.006_bb0075","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1097\/TP.0b013e31818b62c8","article-title":"Progressive multifocal leukoencephalopathy and use of mycophenolate mofetil after kidney transplantation","volume":"86","author":"Neff","year":"2008","journal-title":"Transplantation"},{"key":"10.1016\/j.jneuroim.2017.05.006_bb0080","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1212\/WNL.0000000000000541","article-title":"Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS study","volume":"83","author":"O'connor","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2017.05.006_bb0085","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jneuroim.2016.12.012","article-title":"Lymphocyte subsets as biomarkers of therapeutic response in fingolimod treated relapsing multiple sclerosis patients","volume":"303","author":"Paolicelli","year":"2017","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2017.05.006_bb0090","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/ana.24286","article-title":"Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"76","author":"Plavina","year":"2014","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2017.05.006_bb0095","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2017.05.006_bb0100","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2017.05.006_bb0105","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1177\/1352458515604381","article-title":"Lymphocytosis as a response biomarker of natalizumab therapeutic efficacy in multiple sclerosis","volume":"22","author":"Signoriello","year":"2016","journal-title":"Mult. Scler."},{"key":"10.1016\/j.jneuroim.2017.05.006_bb0110","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/ana.20858","article-title":"Immune surveillance in multiple sclerosis patients treated with natalizumab","volume":"59","author":"Stuve","year":"2006","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2017.05.006_bb0115","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1177\/1352458514556296","article-title":"Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF","volume":"21","author":"Warnke","year":"2015","journal-title":"Mult. Scler."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572817301297?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572817301297?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:29:22Z","timestamp":1759048162000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572817301297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":23,"alternative-id":["S0165572817301297"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2017.05.006","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CD4\/CD8 ratio during natalizumab treatment in multiple sclerosis patients","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2017.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}